about
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technologyHigh-throughput screening to enhance oncolytic virus immunotherapyOncolytic Sendai virus-based virotherapy for cancer: recent advancesOncolytic virotherapy for human malignant mesothelioma: recent advancesUltrasound-mediated oncolytic virus delivery and uptake for increased therapeutic efficacy: state of art.Promising oncolytic agents for metastatic breast cancer treatmentChemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapyOncolytic virotherapy using herpes simplex virus: how far have we come?Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advancesThe ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implicationsOncolytic adenovirus-mediated therapy for prostate cancerOncolytic viral therapy for pancreatic cancer: current research and future directionsOncolytic Seneca Valley Virus: past perspectives and future directionsOncolytic virotherapy for pediatric malignancies: future prospectsThyroid malignant neoplasm-associated biomarkers as targets for oncolytic virotherapySpotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodesMechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapyImmune cells: more than simple carriers for systemic delivery of oncolytic viruses.Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma.Oncolytic virotherapy for ovarian cancer.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Characterization of an Oncolytic Adenovirus Vector Constructed to Target the cMet ReceptorOncolytic herpes viruses, chemotherapeutics, and other cancer drugsLive attenuated measles virus vaccine therapy for locally established malignant glioblastoma tumor cellsReovirus in cancer therapy: an evidence-based reviewMyxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myelomaExtended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.On the potential of oncolytic virotherapy for the treatment of canine cancers.Targeting tumor vasculature through oncolytic virotherapy: recent advances.Myxoma virus therapy for human embryonal rhabdomyosarcoma in a nude mouse model.CXCL12 retargeting of an adenovirus vector to cancer cells using a bispecific adapter.Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.Curative effect of HF10 on liver and peritoneal metastasis mediated by host antitumor immunity.Oncolytic viral therapy: targeting cancer stem cellsApplications of coxsackievirus A21 in oncologyOncolytic virotherapy: the questions and the promise.Oncolytic virus therapy for cancer.Cell carriers for oncolytic viruses: current challenges and future directions.Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma.
P1433
Q26821929-9DAC6539-0B39-415D-AF85-D0B1D95F1C04Q26823674-361DE285-8CCB-4F62-8B60-F84FA1CFE0E8Q26825239-DE186F25-E392-4804-BBCE-B3CDAB58C2AAQ26826590-F9838AF9-A207-40C9-8153-181E7172BF54Q26827216-68C8E985-6C7D-4CFF-81F4-4B09D2D699C1Q26830620-A62A6739-D37E-4B98-B106-8235FD2FAEECQ26852345-BBDD9ED3-9F66-4421-BBD2-C7AA7EC761FBQ26862461-4434E5DE-6B3F-4A0C-ADB9-3260F5D0373AQ26863779-71741291-F467-4F63-A73F-A0778C82823BQ27002660-29594904-63C4-49F7-A213-A9F69A4BEAFFQ27004796-093C577F-CA7A-47D5-9B46-7F1C92C0033FQ27011439-F39DCE79-D033-4EA7-9DB4-281E2739AE41Q27468763-D8AE733C-A3CE-4E46-9FC1-4C3CEF570529Q28069358-90E2842B-5788-46D0-8505-DFA3A25546A2Q28071977-42384AA7-15E6-490D-A874-853201842A22Q28077949-1ECF89C3-40C9-48FB-AAD6-C3CF49A4D5B1Q28083766-C3CF9577-C6AE-4D58-A708-5226431DE8ECQ35162284-4945F069-9EEA-4C84-A70A-B799CE382636Q35317396-CE541716-86CB-4ABF-BDAC-18A51B6974FFQ35597082-754BD07A-CBF3-47D1-B868-B5B8CB7EB357Q36308045-7F1D7625-5E29-4009-B16F-72A391B53720Q36558142-377E2A98-A144-4355-9D48-5795F3584CC1Q37031896-789DC767-7212-42D0-9EF8-E73B2EC3E8D0Q37031905-F63EE74A-67BE-41BB-B428-341DD984B537Q37031909-4A1984DE-A5E4-46D9-B0CA-E02D7BAA3B7FQ37031914-331CA794-00FB-4328-AFB4-6E9DA34D40C4Q37031918-95369188-1568-42E3-BB25-ED7852774748Q37031925-533FB678-F409-4D78-8B7A-B0C7A35E70C8Q37031932-E318758E-E868-4626-A935-FD7BFBD9A23DQ37200546-8BF44C78-9B09-4DEB-911B-83705286D2EFQ37420781-D82F9C6B-E293-47D6-BAC6-AF061D9C2276Q37641495-CCBA922E-7896-4E09-A0FC-D68B0847A311Q37709761-22D50A4B-22C9-4FC0-9924-0E19C4BCC162Q38212255-88933C8F-4FC0-4B75-8853-6F5B673C2EB0Q38564325-65C49651-C431-42DE-8C59-C3807BFBF835Q38924527-2EFE88D0-804E-49EC-B4C4-BA176C95538EQ38924529-B4E1D901-E7FF-488B-8D38-7B7081774AB1Q38924531-380E93E5-ED4A-4C06-B37C-8AA6FF9D5512Q38924539-AFEB1544-C0A3-4D45-8A61-C00D192041E5Q38924543-CE57E81C-4831-4827-A157-3C5E0AAC9DD8
P1433
description
journal
@en
revista científica
@es
wetenschappelijk tijdschrift van Dove Medical Press
@nl
wissenschaftliche Fachzeitschrift
@de
name
Oncolytic virotherapy
@ast
Oncolytic virotherapy
@en
Oncolytic virotherapy
@es
Oncolytic virotherapy
@nl
type
label
Oncolytic virotherapy
@ast
Oncolytic virotherapy
@en
Oncolytic virotherapy
@es
Oncolytic virotherapy
@nl
altLabel
Oncolytic Virother
@en
Oncolytic Virotherapy
@en
prefLabel
Oncolytic virotherapy
@ast
Oncolytic virotherapy
@en
Oncolytic virotherapy
@es
Oncolytic virotherapy
@nl
P31
P3181
P1055
P1476
Oncolytic virotherapy
@en